PMID- 33273981
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231104
IS  - 1792-0981 (Print)
IS  - 1792-1015 (Electronic)
IS  - 1792-0981 (Linking)
VI  - 21
IP  - 1
DP  - 2021 Jan
TI  - Hesperidin prevents hyperglycemia in diabetic rats by activating the insulin 
      receptor pathway.
PG  - 53
LID - 10.3892/etm.2020.9485 [doi]
LID - 53
AB  - Diabetes, a disease with high prevalence in China, is a major risk factor of 
      cardiovascular disease. Hesperidin is a flavanone glycoside with 
      anti-hyperglycemic and anti-hyperlipidemic activities. Therefore, the present 
      study aimed to investigate the potential preventive effect of hesperidin against 
      type 2 diabetes mellitus (T2DM) using a rat model of alloxan and high fat diet 
      (HFD)-induced insulin resistance. Male Sprague Dawley rats were orally 
      administered with 100 mg/kg hesperidin or vehicle (sodium carboxy methyl 
      cellulose) for 35 days. Insulin resistance was induced by feeding animals a HFD 
      for 3 weeks (from day 7) and then with an alloxan injection on day 28. Results 
      from the in vivo study demonstrated that hesperidin improved fasting serum 
      glucose (from 19.8 to 10.6 mmol/l) without changing the fasting insulin level, 
      suggesting that hesperidin prevented the development of insulin resistance and 
      diabetes by improving insulin sensitivity. In the oral glucose tolerance test, 
      the development of impaired glucose tolerance was also prevented by hesperidin 
      treatment. Hesperidin was found to regulate glycolysis and gluconeogenesis by 
      enhancing the activity of glucokinase, inducing the phosphorylation of insulin 
      receptor (IR) and phosphoinositide-dependent kinase 1 (PDK1), while decreasing 
      the activity of glucose-6-phosphatase and phosphoenolpyruvate carboxykinase in 
      the liver. In a cell-based assay, hesperidin increased glucose uptake in primary 
      rat adipocytes. Collectively, the present study identified the potent preventive 
      effect of hesperidin against HFD-induced insulin resistance by activating the 
      IR/PDK1 pathway. The current results may provide a potential strategy lacking 
      sides effects to improve metabolic health and reduce risks.
CI  - Copyright (c) 2020, Spandidos Publications.
FAU - Peng, Peng
AU  - Peng P
AD  - Graduate School, First Affiliated Hospital, Heilongjiang University of Chinese 
      Medicine, Harbin, Heilongjiang 150040, P.R. China.
FAU - Jin, Juan
AU  - Jin J
AD  - The First Department of Cardiovascular, First Affiliated Hospital, Heilongjiang 
      University of Chinese Medicine, Harbin, Heilongjiang 150040, P.R. China.
FAU - Zou, Guoliang
AU  - Zou G
AD  - The First Department of Cardiovascular, First Affiliated Hospital, Heilongjiang 
      University of Chinese Medicine, Harbin, Heilongjiang 150040, P.R. China.
FAU - Sui, Yanbo
AU  - Sui Y
AD  - The First Department of Cardiovascular, First Affiliated Hospital, Heilongjiang 
      University of Chinese Medicine, Harbin, Heilongjiang 150040, P.R. China.
FAU - Han, Yubo
AU  - Han Y
AD  - Graduate School, First Affiliated Hospital, Heilongjiang University of Chinese 
      Medicine, Harbin, Heilongjiang 150040, P.R. China.
FAU - Zhao, Dapeng
AU  - Zhao D
AD  - Department of Nephropathy, First Affiliated Hospital, Heilongjiang University of 
      Chinese Medicine, Harbin, Heilongjiang 150040, P.R. China.
FAU - Liu, Li
AU  - Liu L
AD  - The First Department of Cardiovascular, First Affiliated Hospital, Heilongjiang 
      University of Chinese Medicine, Harbin, Heilongjiang 150040, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20201119
PL  - Greece
TA  - Exp Ther Med
JT  - Experimental and therapeutic medicine
JID - 101531947
PMC - PMC7706385
OTO - NOTNLM
OT  - animal model
OT  - glucose uptake
OT  - insulin resistance
OT  - type 2 diabetes mellitus
EDAT- 2020/12/05 06:00
MHDA- 2020/12/05 06:01
PMCR- 2020/11/19
CRDT- 2020/12/04 05:47
PHST- 2019/02/25 00:00 [received]
PHST- 2020/08/26 00:00 [accepted]
PHST- 2020/12/04 05:47 [entrez]
PHST- 2020/12/05 06:00 [pubmed]
PHST- 2020/12/05 06:01 [medline]
PHST- 2020/11/19 00:00 [pmc-release]
AID - ETM-0-0-09485 [pii]
AID - 10.3892/etm.2020.9485 [doi]
PST - ppublish
SO  - Exp Ther Med. 2021 Jan;21(1):53. doi: 10.3892/etm.2020.9485. Epub 2020 Nov 19.